<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02051218</url>
  </required_header>
  <id_info>
    <org_study_id>SAKK 96/12</org_study_id>
    <secondary_id>000000685</secondary_id>
    <secondary_id>2014-001189-87</secondary_id>
    <nct_id>NCT02051218</nct_id>
  </id_info>
  <brief_title>Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks</brief_title>
  <official_title>Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks - A Non-Inferiority Phase III Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Swiss Group for Clinical Cancer Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Swiss Group for Clinical Cancer Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the trial is to test the hypothesis that the benefit of denosumab is maintained if
      administered only every 12 weeks as compared to every 4 weeks.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Denosumab, a monoclonal antibody against RANK-Ligand has been shown superior to zoledronic
      acid in delaying time to a first on-study skeletal related event (SRE) in patients with solid
      tumors, with no effects on disease progression or survival. Many SREs were silent compression
      fractures found only because of scheduled imaging. The approved dose of denosumab is 120 mg
      s.c. every 4 weeks (q4w). Although generally well tolerated, there is a time-dependent
      increase in osteonecrosis of the jaw in up to 8% of patients. Cases of fatal hypocalcaemia
      were observed during post marketing surveillance.

      The optimal dose and schedule for denosumab is unknown. Denosumab is associated with
      considerable costs and may add toxicity; thus a study of de-escalation is warranted.

      The aim of the trial is to test the hypothesis that the benefit of Denosumab is maintained if
      administered 120 mg q12w as compared to 120 mg q4w. The primary endpoint of this open-label
      randomized phase III non-inferiority trial is time to first on-trial symptomatic skeletal
      event (SSE: i.e. clinically significant pathological fracture, radiation therapy to bone,
      surgery to bone or spinal cord compression). With a non-inferiority margin of 1.2 for the
      hazard ratio, a power 80% and a type I error 5%, the total sample size is 1380. Secondary
      endpoints are safety, time to subsequent on-trial SSE, quality of life, health economic
      outcomes, and change in bone turnover markers. This study is open for international
      collaboration.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 16, 2014</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to first on-trial symptomatic skeletal event (SSE; Clinically significant pathological fracture, radiation therapy to bone, surgery to bone or spinal cord compression).</measure>
    <time_frame>at the latest 5 years after randomization.</time_frame>
    <description>A SSE is defined as one of the following events: Clinically significant pathological fracture, radiation therapy to bone, surgery to bone, or spinal cord compression.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity (focus on hypocalcaemia and osteonecrosis of the jaw)</measure>
    <time_frame>at the latest 5 years after randomization.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first and subsequent on-trial SSE</measure>
    <time_frame>at the latest 5 years after randomization.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>at the latest 5 years after randomization.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skeletal morbidity period rate (SMPR)</measure>
    <time_frame>at the latest 5 years after randomization.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skeletal morbidity rate (SMR)</measure>
    <time_frame>at the latest 5 years after randomization.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health economic analysis</measure>
    <time_frame>at the latest 5 years after randomization.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone turnover markers</measure>
    <time_frame>at the latest 5 years after randomization.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>at the latest 5 years after randomization.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1380</enrollment>
  <condition>Metastatic Breast Cancer</condition>
  <condition>Metastatic Prostate Cancer</condition>
  <condition>Bone Metastases</condition>
  <arm_group>
    <arm_group_label>Arm A (standard arm)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Denosumab 120mg (XGEVA®) sc. q4w</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B (reduced arm)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Denosumab 120mg (XGEVA®) sc. q4w [weeks 1, 5, 9] followed by Denosumab 120mg (XGEVA®) sc. q12w [weeks 13, 25, …]</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Denosumab (reduced dosing)</intervention_name>
    <description>3x Denosumab 120mg (XGEVA®) sc. q4w followed by Denosumab 120mg (XGEVA®) sc. q12w</description>
    <arm_group_label>Arm B (reduced arm)</arm_group_label>
    <other_name>XGEVA®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Denosumab (standard dosing)</intervention_name>
    <description>Denosumab 120mg (XGEVA®) sc. q4w</description>
    <arm_group_label>Arm A (standard arm)</arm_group_label>
    <other_name>XGEVA®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient has given written informed consent.

          -  Histologically confirmed diagnosis of breast or prostate cancer before randomization.

          -  Patient has metastatic breast cancer (stage IV, all subtypes allowed) or prostate
             cancer (stage IV) and bone metastases and is planned to receive or is receiving
             antineoplastic treatment.

          -  Patients with prostate cancer must have evidence of disease progression on continuous
             androgen deprivation therapy (CRPC).

          -  Patients must have ≥ 3 bone metastases (lytic or blastic or mixed). The lesions must
             be documented by radiological evaluation within 12 weeks before randomization (by
             X-Ray, CT scan, PET-CT, MRI scan or bone scintigraphy).

          -  WHO performance status 0-2

          -  Age ≥ 18 years.

          -  Corrected serum calcium ≥ 2 mmol/l and ≤ 3 mmol/l (medical treatments to obtain serum
             calcium levels in the normal range are allowed, as far as no denosumab is used.
             Maximally 1 dose of bisphosphonates in the case of hypercalcemia is allowed, if the
             bisphosphonate was applied at least 3 weeks before the first dose of denosumab).

          -  Liver transaminases not more than 1.5 x ULN or not more than 3 x ULN with liver
             metastases. Serum total bilirubin ≤ 1.5 x ULN (≤ 2.0 x ULN in case of known Gilbert's
             disease)

          -  Women are not breastfeeding. Women with child-bearing potential are using effective
             contraception, are not pregnant and agree not to become pregnant during participation
             in the trial and during the 12 months thereafter. A negative pregnancy test before
             inclusion (within 7 days) into the trial is required for all women with child-bearing
             potential.

          -  Men agree not to father a child during participation in the trial and during 12 months
             thereafter.

        Exclusion Criteria:

          -  Definite contraindication for denosumab (e.g. hypocalcaemia [Albumin-corrected serum
             calcium &lt; 2.0 mmol/l]).

          -  History or current evidence of osteonecrosis of the jaw.

          -  Non-healed mucosa in oral cavity (by surgery or as a side effect of any other
             treatment).

          -  Jaw or dental conditions that require oral surgery or if surgery or invasive dental
             procedures are planned.

          -  Prior use of denosumab for bone metastases (dose 120 mg every 4 weeks) or
             bisphosphonates to treat bone metastases. Patients treated with denosumab or
             bisphosphonates against osteopenia or osteoporosis are allowed to enter the trial if
             the last dose was more than 28 days before randomization.

          -  Patients with known osteoporosis (T-score ≤ -2.5) at study entry (since fractures from
             osteoporosis are difficult to be discriminated from fractures through bone
             metastases).

          -  Radiotherapy or surgery to the bone within the last two weeks before randomization or
             planned within 6 weeks after randomization.

          -  Presence or history of CNS metastases or leptomeningeal disease. A MRI evaluation
             within 12 weeks before randomization must be performed in case of suspicious symptoms.

          -  Psychiatric disorder precluding understanding of information on trial related topics,
             giving informed consent, filling out QoL forms.

          -  Concurrent treatment in a clinical trial with SSE or SRE as primary endpoint.

          -  Known hypersensitivity to trial drug or hypersensitivity to any other component of the
             trial drug (e.g. fructose).

          -  Any concomitant drugs contraindicated for use with the trial drugs according to the
             approved product information.

          -  Any psychological, familial, sociological or geographical condition potentially
             hampering compliance with the trial protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roger von Moos, PD MD</last_name>
    <role>Study Chair</role>
    <affiliation>Kantonsspital Graubünden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Arnoud Templeton, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Cantonal Hospital of St. Gallen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Silke Gillessen, Prof</last_name>
    <role>Study Chair</role>
    <affiliation>Cantonal Hospital of St. Gallen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andreas Müller, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Kantonsspital Winterthur KSW</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andrea Fuhrer, PhD</last_name>
    <phone>+41 31 389 91 91</phone>
    <email>trials@sakk.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>Uniklinik Düsseldorf, Urologische Klinik</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anja Lorch, Prof</last_name>
      <phone>+49 211 81 08776</phone>
      <email>anja.lorch@med.uni-duesseldorf.de</email>
    </contact>
    <investigator>
      <last_name>Anja Lorch, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Düsseldorf, Frauenheilkunde/Geburtshilfe</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eugen Ruckhäberle, Prof</last_name>
      <phone>+49 311 81-08087</phone>
      <email>eugen.ruckhaeberle@med.uni-duesseldorf.de</email>
    </contact>
    <investigator>
      <last_name>Eugen Ruckhäberle, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hirslanden Klinik Aarau</name>
      <address>
        <city>Aarau</city>
        <zip>CH-5001</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Razvan Popescu, MD</last_name>
      <phone>+41 62 836 78 30</phone>
      <email>Razvan.Popescu@hirslanden.ch</email>
    </contact>
    <investigator>
      <last_name>Razvan Popescu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kantonspital Aarau</name>
      <address>
        <city>Aarau</city>
        <zip>CH-5001</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tobias Wehrhahn, MD</last_name>
      <phone>+41 62 838 59 27</phone>
      <email>tobias.wehrhahn@ksa.ch</email>
    </contact>
    <investigator>
      <last_name>Tobias Wehrhahn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Baden</name>
      <address>
        <city>Baden</city>
        <zip>CH-5404</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Priska Bützberger, MD</last_name>
      <phone>+41 56 486 27 62</phone>
      <email>priska.buetzberger@ksb.ch</email>
    </contact>
    <investigator>
      <last_name>Priska Bützberger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitaetsspital Basel</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sacha Rothschild, MD</last_name>
      <phone>+41 61 265 25 25</phone>
      <email>sacha.rothschild@usb.ch</email>
    </contact>
    <investigator>
      <last_name>Sacha Rothschild, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brustzentrum Basel - Praxis für ambulante Tumortherapie</name>
      <address>
        <city>Basel</city>
        <zip>4052</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Roger Thorn, MD</last_name>
      <phone>+41 61 279 98 22</phone>
      <email>dr.david.thorn@hin.ch</email>
    </contact>
    <investigator>
      <last_name>David Roger Thorn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Claraspital AG</name>
      <address>
        <city>Basel</city>
        <zip>CH-4016</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arnoud Templeton, MD</last_name>
      <phone>+41 61 685 83 30</phone>
      <email>arnoud.templeton@unibas.ch</email>
    </contact>
    <investigator>
      <last_name>Arnoud Templeton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Oncologico della Svizzera Italiana - Ospedale Regionale Bellinzona e Valli</name>
      <address>
        <city>Bellinzona</city>
        <zip>6500</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivia Pagani, MD</last_name>
      <phone>+41 91 811 84 35</phone>
      <email>olivia.pagani@ibcsg.org</email>
    </contact>
    <investigator>
      <last_name>Olivia Pagani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinik Engeried / Praxis Oncocare</name>
      <address>
        <city>Bern</city>
        <zip>3012</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katharina Buser, MD</last_name>
      <phone>+41 31 309 95 01</phone>
      <email>kbuser@oncocare.ch</email>
    </contact>
    <investigator>
      <last_name>Katharina Buser, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inselspital, Bern</name>
      <address>
        <city>Bern</city>
        <zip>CH-3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julian Schardt, MD</last_name>
      <phone>+41 31 632 11 55</phone>
      <email>julian.schardt@insel.ch</email>
    </contact>
    <investigator>
      <last_name>Julian Schardt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spitalzentrum Biel</name>
      <address>
        <city>Biel</city>
        <zip>CH-2501</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Zweifel, MD</last_name>
      <phone>+41 32 324 36 62</phone>
      <email>martin.zweifel@szb-chb.ch</email>
    </contact>
    <investigator>
      <last_name>Martin Zweifel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spitalzentrum Oberwallis</name>
      <address>
        <city>Brig</city>
        <zip>3900</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine Mengis Bay, MD</last_name>
      <phone>+41 27 604 36 60</phone>
      <email>catherine.mengis@hopitalvs.ch</email>
    </contact>
    <investigator>
      <last_name>Catherine Mengis Bay, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Graubünden</name>
      <address>
        <city>Chur</city>
        <zip>7000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roger von Moos, MD, PD</last_name>
      <phone>+41 81 256 66 47</phone>
      <email>roger.vonmoos@ksgr.ch</email>
    </contact>
    <investigator>
      <last_name>Roger von Moos, MD, PD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Frauenfeld - Brustzentrum</name>
      <address>
        <city>Frauenfeld</city>
        <zip>8501</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mathias Fehr, MD</last_name>
      <phone>+41 52 723 72 53</phone>
      <email>mathias.fehr@stgag.ch</email>
    </contact>
    <investigator>
      <last_name>Mathias Fehr, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Fribourgeois</name>
      <address>
        <city>Fribourg</city>
        <zip>1708</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc Küng, MD</last_name>
      <phone>+41 26 426 72 43</phone>
      <email>marc.kueng@h-fr.ch</email>
    </contact>
    <investigator>
      <last_name>Marc Küng, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopitaux Universitaires de Geneve</name>
      <address>
        <city>Genève 14</city>
        <zip>1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandre Bodmer, MD</last_name>
      <phone>+41 22 372 40 14</phone>
      <email>alexandre.bodmer@hcuge.ch</email>
    </contact>
    <investigator>
      <last_name>Alexandre Bodmer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital neuchâtelois</name>
      <address>
        <city>La Chaux-de-Fonds</city>
        <zip>2300</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Agnes Auteri, MD</last_name>
      <phone>+41 79 559 41 93</phone>
      <email>agnes.auteri@h-ne.ch</email>
    </contact>
    <investigator>
      <last_name>Agnes Auteri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CCAC Lausanne</name>
      <address>
        <city>Lausanne</city>
        <zip>1004</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre Bohanes, MD</last_name>
      <phone>+41 (21) 646 79 94</phone>
      <email>pbohanes@bluewin.ch</email>
    </contact>
    <investigator>
      <last_name>Pierre Bohanes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHUV</name>
      <address>
        <city>Lausanne</city>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Khalil Zaman, MD</last_name>
      <phone>+41 79 556 78 01</phone>
      <email>khalil.zaman@chuv.ch</email>
    </contact>
    <investigator>
      <last_name>Khalil Zaman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Liestal</name>
      <address>
        <city>Liestal</city>
        <zip>CH-4410</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bettina Seifert, MD</last_name>
      <phone>+41 61 925 34 03</phone>
      <email>bettina.seifert@ksli.ch</email>
    </contact>
    <investigator>
      <last_name>Bettina Seifert, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione Oncologia / Oncologia ematologia</name>
      <address>
        <city>Locarno</city>
        <zip>6600</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Augusto Pedrazzini, MD</last_name>
      <phone>+41 91 752 3535</phone>
      <email>a.pedrazzini@oncologia-pedrazzini.ch</email>
    </contact>
    <investigator>
      <last_name>Augusto Pedrazzini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oncologia Varini &amp; Calderoni &amp; Christinat</name>
      <address>
        <city>Lugano</city>
        <zip>6900</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonello Calderoni, MD</last_name>
      <phone>+41 91 922 69 88</phone>
      <email>antonello@calderoni.ch</email>
    </contact>
    <investigator>
      <last_name>Antonello Calderoni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Luzerner Kantonsspital</name>
      <address>
        <city>Luzern</city>
        <zip>6000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ralph Winterhalder, MD</last_name>
      <phone>+41 41 205 58 75</phone>
      <email>ralph.winterhalder@luks.ch</email>
    </contact>
    <investigator>
      <last_name>Ralph Winterhalder, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hirslanden Klinik St. Anna Luzern</name>
      <address>
        <city>Luzern</city>
        <zip>6006</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Spirig, MD</last_name>
      <phone>+41 41 208 32 10</phone>
      <email>Christian.Spirig@hirslanden.ch</email>
    </contact>
    <investigator>
      <last_name>Christian Spirig, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Muensterlingen</name>
      <address>
        <city>Münsterlingen</city>
        <zip>8596</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roman Inauen, MD</last_name>
      <phone>+41 71 686 11 11</phone>
      <email>roman.inauen@stgag.ch</email>
    </contact>
    <investigator>
      <last_name>Roman Inauen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Olten</name>
      <address>
        <city>Olten</city>
        <zip>4600</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catrina Uhlmann Nussbaum, MD</last_name>
      <phone>+41 62 311 42 41</phone>
      <email>cuhlmann_ol@spital.ktso.ch</email>
    </contact>
    <investigator>
      <last_name>Catrina Uhlmann Nussbaum, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spital Limmattal</name>
      <address>
        <city>Schlieren</city>
        <zip>8952</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alix Stern, MD</last_name>
      <phone>+41 44 733 22 48</phone>
      <email>alix.stern@spital-limmattal.ch</email>
    </contact>
    <investigator>
      <last_name>Alix Stern, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital du Valais Sion</name>
      <address>
        <city>Sion</city>
        <zip>1951</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandro Anchisi, Dr. med.</last_name>
      <phone>+41 (27) 603 45 00</phone>
      <email>sandro.anchisi@hopitalvs.ch</email>
    </contact>
    <investigator>
      <last_name>Sandro Anchisi, Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bürgerspital Solothurn - Onkologiezentrum</name>
      <address>
        <city>Solothurn</city>
        <zip>4600</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe von Burg, MD</last_name>
      <phone>+41 32 627 47 00</phone>
      <email>philippe.vonburg@spital.so.ch</email>
    </contact>
    <investigator>
      <last_name>Philippe von Burg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zentrum fuer Tumordiagnostikund Praevention</name>
      <address>
        <city>St. Gallen</city>
        <zip>CH-9006</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Friedemann Honecker, MD</last_name>
      <phone>+41 71 243 00 43</phone>
      <email>friedemann.honecker@zetup.ch</email>
    </contact>
    <investigator>
      <last_name>Friedemann Honecker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kantonsspital St. Gallen</name>
      <address>
        <city>St. Gallen</city>
        <zip>CH-9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sabine Schmid, MD</last_name>
      <phone>+41 71 494 11 11</phone>
      <email>sabine.schmid@kssg.ch</email>
    </contact>
    <investigator>
      <last_name>Sabine Schmid, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spital STS AG</name>
      <address>
        <city>Thun</city>
        <zip>3600</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Rauch, MD</last_name>
      <phone>+41 58 636 26 45</phone>
      <email>daniel.rauch@spitalstsag.ch</email>
    </contact>
    <investigator>
      <last_name>Daniel Rauch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Winterthur</name>
      <address>
        <city>Winterthur</city>
        <zip>8401</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Müller, MD</last_name>
      <phone>41-052-266-2552</phone>
      <email>Andreas.mueller@ksw.ch</email>
    </contact>
    <investigator>
      <last_name>Andreas Müller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Onkozentrum Klinik im Park</name>
      <address>
        <city>Zurich</city>
        <zip>8038</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Urs Huber, MD</last_name>
      <phone>41-43-344-3333</phone>
      <email>huber@1st.ch</email>
    </contact>
    <investigator>
      <last_name>Urs Huber, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brustzentrum-Zürich</name>
      <address>
        <city>Zürich</city>
        <zip>8005</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Trojan, Prof</last_name>
      <phone>+41 (43) 344 33 33</phone>
      <email>trojan@1st.ch</email>
    </contact>
    <investigator>
      <last_name>Andreas Trojan, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hirslanden Onkozentrum Zürich</name>
      <address>
        <city>Zürich</city>
        <zip>8032</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas von Briel, Dr. med.</last_name>
      <phone>+41 (44) 387 35 35</phone>
      <email>vonbriel@onkozentrum.ch</email>
    </contact>
    <investigator>
      <last_name>Thomas von Briel, Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsspital Zürich</name>
      <address>
        <city>Zürich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Hermanns, MD</last_name>
      <phone>+41 44 255 51 67</phone>
      <email>thomas.hermanns@usz.ch</email>
    </contact>
    <investigator>
      <last_name>Thomas Hermanns, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stadtspital Triemli</name>
      <address>
        <city>Zürich</city>
        <zip>CH-8063</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susanna Stoll, MD</last_name>
      <phone>+41 44 416 34 75</phone>
      <email>susanna.stoll@triemli.stzh.ch</email>
    </contact>
    <investigator>
      <last_name>Susanna Stoll, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 29, 2014</study_first_submitted>
  <study_first_submitted_qc>January 29, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 31, 2014</study_first_posted>
  <last_update_submitted>May 22, 2018</last_update_submitted>
  <last_update_submitted_qc>May 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>metastatic breast cancer</keyword>
  <keyword>castration resistant metastatic prostate cancer</keyword>
  <keyword>bone metastases</keyword>
  <keyword>Denosumab</keyword>
  <keyword>XGEVA</keyword>
  <keyword>de-escalation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Denosumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

